| Literature DB >> 32457610 |
Chan Li1,2, Junying Huang1, Yung-Chi Cheng2, Yuan-Wei Zhang1,2.
Abstract
Depression is a multigenetic or multifactorial syndrome. The central neuron system (CNS)-orientated, single target, and conventional antidepressants are insufficient and far from ideal. Traditional Chinese Medicine (TCM) has historically been used to treat depression up till today, particularly in Asia. Its holistic, multidrug, multitarget nature fits well with the therapeutic idea of systems medicine in depression treatment. Over the past two decades, although efforts have been made to understand TCM herbal antidepressants at the molecular level, many fundamental questions regarding their mechanisms of action remain to be addressed at the systems level in order to better understand the complicated herbal formulations in depression treatment. In this Mini Review, we review and discuss the mechanisms of action of herbal antidepressants and their acting targets in the pathological systems in the brain, such as monoamine neurotransmissions, hypothalamic-pituitary-adrenal (HPA) axis, neurotropic factor brain-derived neurotrophic factor (BDNF) cascade, and glutamate transmission. Some herbal molecules, constituents, and formulas are highlighted as examples to discuss their mechanisms of action and future directions for comprehensive researches at the systems level. Furthermore, we discuss pharmacological approaches to integrate the mechanism of action from the molecular level into the systems level for understanding of systems pharmacology of TCM formulations. Integration of the studies at the molecular level into the systems level not only represents a trend in TCM study but also promotes our understanding of the system-wide mechanism of action of herbal antidepressant formulations.Entities:
Keywords: depression treatment; mechanism of action; neuropharmacology; systems pharmacology; traditional Chinese medicine
Year: 2020 PMID: 32457610 PMCID: PMC7221138 DOI: 10.3389/fphar.2020.00586
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Figure 1Several divergent systems in the CNS are involved in the pathophysiology of depression. The pathophysiological systems in the CNS that herbal antidepressants are proposed to act on include monoamine neurotransmissions, the HPA axis, neurotrophins, and synapse number and function as shown. Dysfunction of these systems leads to increased incidence of depression. Correspondingly, antidepressant discovery efforts toward these systems have provided numerous pharmacological targets, which include enhancement of monoaminergic transmissions, dehyperactivation of HPA axis, elevation of neurotrophic factor expression, and stimulation of glutamatergic transmission. Given space limitations, other factors in the pathophysiology of depression, such as the proinflammatory cytokines, the gastrointestinal system, ovarian steroids, vascular endothelial growth factor, and gene polymorphisms are not shown and discussed in this Mini Review.
Herbal constituents that produce antidepressant-like activities in animal models or cells.
| Structural category | Herbal constituents | Herbs | Mechanism of action | Models | Administration dosage | Treatment time | Reference |
|---|---|---|---|---|---|---|---|
| Total saponins | The HPA axis/BDNF | CUMS rats | 12.5, 25,50 mg/kg, i.g. | 6 weeks | ( | ||
| Sarsasapogenin | Monoamine | CUMS mice | 12.5, 25, 50 mg/kg, p.o. | 14 days | ( | ||
| Ginsenoside Rb1 | Monoamine | mice | 4, 8, 16 mg/kg, p.o. | 7 days | ( | ||
| mice | 5, 10, 20 mg/kg, p.o. | 60 min | ( | ||||
| BDNF | CUMS mice | 20 mg/kg, p.o. | 21 days | ( | |||
| Ginsenoside Rg3 | The HPA axis | CUS rats | 20, 40 mg/kg, i.g. | 14 days | ( | ||
| BDNF | CSDS mice | 10, 20 mg/kg, i.p. | 14 days | ( | |||
| Glutamate transmission/BDNF | CMS mice | 50, 100, 150 mg/kg, i.g. | 4 weeks | ( | |||
| Ginsenoside Rg1 | BDNF | CUMS rats | 40 mg/kg, i.p. | 5 weeks | ( | ||
| Ginsenoside Rg5 | BDNF | CSDS mice | 5, 10, 20, 40 mg/kg, i.p. | 14 days | ( | ||
| Saikosaponin A | Monoamine | CUMS rats | 50 mg/kg, i.g. | 4 weeks | ( | ||
| Saikosaponin D | The HPA axis | CUMS rats | 0.75 and 1.50 mg/kg, i.g. | 21 days | ( | ||
| YY-21 | BDNF | CMS rats | 10 mg/kg, i.g. | 3 weeks | ( | ||
| YY-23 | Glutamate transmission | CMS mice | 20 mg/kg, i.g. | 3 weeks | ( | ||
| Yuanzhi-1 | Monoamine | CMS rats | 2.5, 5, 10 mg/kg, p.o. | 38 days | ( | ||
| YZ-50 | BDNF | CMS rats | 140 and 280 mg/kg, i.g. | 28 days | ( | ||
| Icariin | The HPA axis | SDM mice | 25 and 50 mg/kg, i.g. | 28 days | ( | ||
| 20( | BDNF | CSDS mice | 20 and 40 μmol/kg, i.p. | 14 days | ( | ||
| Salidroside | The HPA axis/BDNF | Behavioral despair rats | 20, 40 mg/kg, p.o. | 14 days | ( | ||
| Total glycosides | BDNF | CORT-induced rats | 160 mg/kg, p.o. | 21 days | ( | ||
| Gentiopicroside | Glutamate transmission | Reserpine-induced mice | 50, 100, 200 mg/kg, i.g. | 3 days | ( | ||
| Gastrodin | BDNF | CUS rats | 50, 100, 200 mg/kg, i.p. | 14 days | ( | ||
| Paeoniflorin | BDNF | CUMS mice | 20 mg/kg, i.p. | 30 days | ( | ||
| Flavonoid Extract | BDNF | CORT-induced PC12 Cells | 25, 50, 100 μg/ml | 48 hours | ( | ||
| Pueraria isoflavone | BDNF | Ovariectomy mice | 10 and 100 mg/kg | 8 weeks | ( | ||
| Puerarin | Monoamine/the HPA axis | CUS rats | 60 and 120 mg/kg, i.g. | 20 days | ( | ||
| BDNF | Perimenopausal depression mice | 30, 60, 120 mg/kg, i.g. | 8 or 14 days | ( | |||
| Curcumin | Monoamine/the HPA axis/BDNF | CUMS rats | 2.5, 5 and 10 mg/kg, p.o. | 21 days | ( | ||
| CUMS rats | 40 mg/kg, i.p. | 6 weeks | ( | ||||
| WKY rats | 50, 100, 200 mg/kg, i.p. | 10 days | ( | ||||
| Genistein | Monoamine | Mice | 5, 15, 45 mg/kg, p.o. | 3 weeks | ( | ||
| Baicalein | BDNF | CMS rats | 1, 2, 4 mg/kg, i.p. | 21 days | ( | ||
| Isorhynchophylline | Monoamine | Mice | 10, 20, 40 mg/kg, i.g. | 7 days | ( | ||
| Berberine Chloride | Monoamine | Male albino mice | 5, 10, 20 mg/kg, i.p | 15 days | ( | ||
| Piperine | BDNF | CORT-induced mice | 5, 10 mg/kg, i.p. | 21 days | ( | ||
| Tetrandrine | Monoamine/BDNF | CUMS rats | 10, 20, 40 mg/kg, i.g. | 2 weeks | ( | ||
| Total alkaloid | BDNF | Ovariectomized mice | 10, 30 mg/kg, i.g. | 7 days | ( | ||
| Scopolamine | Glutamate transmission | 25 μg/kg, i.p. | 48 hours/3 times | ( | |||
| Huperzine A | Monoamine/BDNF/Glutamate transmission | 0.05 and 0.15 mg/kg, i.g. | 4 weeks | ( | |||
| Oligosaccharide | The HPA axis | CORT-induced PC12 cells | 5, 10, 125, 500 μM | 5 days | ( | ||
| CUS mice | 12.5, 25, 50 mg/kg, i.g. | 14 days | ( | ||||
| Fuzi polysaccharide 1 | BDNF | Mice | 50, 100 mg/kg, i.p. | 14 days | ( | ||
| Chiisanoside | BDNF | LPS-induced mice | 2.5 and 5 mg/kg, i.p. | 7 days | ( | ||
| Emodi | BDNF | CUMS mice | 20, 40, 80 mg/kg, i.g | 21 days | ( | ||
| Resveratrol | Monoamine | depression mice | 30 mg/kg, p.o. | 3 weeks | ( | ||
| The HPA axis/BDNF | Mice | 20, 40, 80 mg/kg, i.p. | 21 days | ( | |||
| BDNF | LPS-induced mice/CUMS rats | 80 mg/kg, i.p. | 7 days/5 weeks | ( | |||
| Trans-resveratrol | Monoamine | CUS rats | 40, 80 mg/kg, i.g. | 21 days | ( | ||
| Rosmarinic acid | BDNF | CUS rats | 5 and 10 mg/kg, i.p. | 14 days | ( | ||
| Crocin | BDNF | Rats | 12.5, 25, 50 mg/kg, i.p. | 21 days | ( | ||
| Cucurbitacin IIa | BDNF | CUMS mice | 2.5, 5 mg/kg, i.p. | 5 weeks | ( | ||
| Hyperforin | BDNF | mice | 4 mg/kg, i.p. | 4 weeks | ( | ||
| Glutamate transmission | Cortical neurons of rats | 10 µM | 9-12 days | ( | |||
| Bakuchiol analogs | Monoamine | Tr-CHO cells | 0.03-333 µM | 20 min | ( | ||
| Honokiol | The HPA axis/BDNF | CUMS rats | 2, 4, 8 mg/kg, i.g. | 21 days | ( | ||
| Macranthol | BDNF | CUMS mice | 10, 20, 40 mg/kg, p.o. | 5 weeks | ( |
Herbal constituents are listed according to their structural category and their sources, mechanism of action, animal models, and administration dosage and time are also given. Although TCM formulas have been shown to work more efficiently than single constituents or herbs in clinical practice, single molecules or herbs are often used for interpreting the mechanism of action at the molecular level due to the constituent complexity and drug–drug interactions of TCM formulas. For understanding the mechanism of action of a TCM formula at the systems level, it is essential to integrate the molecular mechanism into the system-wide mechanism of action. The representative TCM formulas in depression treatment are, but no limited to, Xiao-Yao-San (Chen et al., 2008), Kai-Xin-San (Fu et al., 2020), Jie-Yu-Wan (Feng et al., 2018), Shu-Yu-San (Chen et al., 2012), Chaihu-Jia-Longgu-Muli-Tang (Li et al., 2011), and so on. CUMS, chronic unpredictable mild stress; CSDS, chronic social defeat stress; CMS, chronic mild stress; SDM, social defeat model; CORT, corticosterone; CUS, chronic unpredictable stress; WKT, Wistar Kyoto; LPS, lipopolysaccharides.